SA
Create Free Alerts
Exact Sciences CorporationEXASNASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
businesswire.com

Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri.

Bridgefront Capital LLC Buys Shares of 11,994 Exact Sciences Corporation $EXAS
defenseworld.net

Bridgefront Capital LLC Buys Shares of 11,994 Exact Sciences Corporation $EXAS

Bridgefront Capital LLC bought a new position in Exact Sciences Corporation (NASDAQ: EXAS) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 11,994 shares of the medical research company's stock, valued at approximately $656,000. Several other institutional investors have also recently made changes to their

Exact Sciences Corporation $EXAS Shares Bought by Dimensional Fund Advisors LP
defenseworld.net

Exact Sciences Corporation $EXAS Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 12.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,188,864 shares of the medical research company's stock after buying an additional 239,313 shares

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
businesswire.com

Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world. Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to t.

Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration
businesswire.com

Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rat.

DNB Asset Management AS Raises Position in Exact Sciences Corporation $EXAS
defenseworld.net

DNB Asset Management AS Raises Position in Exact Sciences Corporation $EXAS

DNB Asset Management AS boosted its position in Exact Sciences Corporation (NASDAQ: EXAS) by 15.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 246,639 shares of the medical research company's stock after purchasing an additional 33,071 shares

Exact Sciences Stockholders Approve Acquisition by Abbott
businesswire.com

Exact Sciences Stockholders Approve Acquisition by Abbott

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.

Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS
defenseworld.net

Aberdeen Group plc Increases Stock Position in Exact Sciences Corporation $EXAS

Aberdeen Group plc raised its holdings in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 52.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 304,609 shares of the medical research company's stock after acquiring an additional 105,138 shares during the quarter.

Exact Sciences Corporation $EXAS Shares Sold by AlphaQuest LLC
defenseworld.net

Exact Sciences Corporation $EXAS Shares Sold by AlphaQuest LLC

AlphaQuest LLC cut its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 89.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 898 shares of the medical research company's stock after selling 7,641 shares during the

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
seekingalpha.com

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance